247 related articles for article (PubMed ID: 22313636)
1. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Yang F; Jove V; Chang S; Hedvat M; Liu L; Buettner R; Tian Y; Scuto A; Wen W; Yip ML; Van Meter T; Yen Y; Jove R
Cancer Biol Ther; 2012 Apr; 13(6):349-57. PubMed ID: 22313636
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
[TBL] [Abstract][Full Text] [Related]
3. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
Voutsadakis IA; Patrikidou A; Tsapakidis K; Karagiannaki A; Hatzidaki E; Stathakis NE; Papandreou CN
Int J Colorectal Dis; 2010 Jul; 25(7):795-804. PubMed ID: 20397022
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
6. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
7. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma.
Ohshima-Hosoyama S; Davare MA; Hosoyama T; Nelon LD; Keller C
J Neurooncol; 2011 Dec; 105(3):475-83. PubMed ID: 21633906
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Baradari V; Höpfner M; Huether A; Schuppan D; Scherübl H
World J Gastroenterol; 2007 Sep; 13(33):4458-66. PubMed ID: 17724801
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.
Spiller SE; Logsdon NJ; Deckard LA; Sontheimer H
BMC Cancer; 2011 Apr; 11():136. PubMed ID: 21492457
[TBL] [Abstract][Full Text] [Related]
11. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
12. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Huang J; Ding T; Yang M; Liu H; Sun X; Jin J
Int J Hematol; 2011 Apr; 93(4):482-493. PubMed ID: 21451957
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.
Jantus-Lewintre E; Sarsotti E; Terol MJ; Benet I; García-Conde J
Clin Transl Oncol; 2006 Nov; 8(11):805-11. PubMed ID: 17134969
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
16. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
17. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
18. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
Yeung BH; Huang DC; Sinicrope FA
J Biol Chem; 2006 Apr; 281(17):11923-32. PubMed ID: 16446371
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
20. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]